Feature

Blood Cancer Emergencies: Hematologists’ Late-Night Calls


 

Tumor lysis syndrome

While it’s rare, tumor lysis syndrome can occur when tumors release their content into blood stream. According to Dr. Sekeres, this can happen when “cancers that grow so quickly that they can start to outgrow their own blood supply and start dying before we even treat patients. When this happens, it causes electrolyte disarray.”

It’s crucial to understand the potential for patients to quickly get worse, he said. He advises clinicians to aggressively check lab values for electrolyte abnormalities and aggressively administer IV fluids and electrolyte replacement when needed. “It’s also important to let the intensive care unit know that they may need to be activated,” he said. Fortunately, he noted, patients can often be stabilized.

Differentiation syndrome

According to the Cleveland Clinic, medications used to treat acute myeloid leukemia and acute promyelocytic leukemia cause cancer cells to differentiate from immature states to mature normal states. But the process can go awry when fluid leaks out of blood vessels in a condition called differentiation syndrome. This can cause multiple problems, Dr. Sekeres said.

A 2020 report noted the potential for “acute end-organ damage with peripheral edema, hypotension, acute renal failure, and interstitial pulmonary infiltrates.”

In these cases, aggressive supportive management is key, Dr. Sekeres said. If a patient is having difficulty breathing, for example, they’ll need electrolyte management and perhaps support via a respirator, he said.

“Most people with acute promyelocytic leukemia can fully recover from differentiation syndrome with prompt, effective treatment,” the Cleveland Clinic notes. It adds that the disease is “highly curable.”

In all of these emergent crises, Dr. Sekeres said, it’s important for hematologists understand that “patients can get very sick very quickly,” and it’s important to intervene early and often.

Dr. Sekeres serves on advisory boards for BMS and Curium Pharma. Dr. Estes and Dr. Boysen-Osborn have no disclosures.

Pages

Recommended Reading

Extraordinary Patients Inspired Father of Cancer Immunotherapy
MDedge Hematology and Oncology
Non-Radical Surgery a Win-Win for Early Cervical Cancer
MDedge Hematology and Oncology
New Drug Approvals Are the Wrong Metric for Cancer Policy
MDedge Hematology and Oncology
Secondary Cancers Post CAR T Therapy: A Concern?
MDedge Hematology and Oncology
Most Cancer Trial Centers Located Closer to White, Affluent Populations
MDedge Hematology and Oncology
Minimally Invasive Cytoreductive Approach Comparable to Open Surgery for Ovarian Cancer
MDedge Hematology and Oncology
Few Childhood Cancer Survivors Get Recommended Screenings
MDedge Hematology and Oncology
It Takes a Village: Treating Patients for NSCLC Brain Metastases
MDedge Hematology and Oncology
Active Surveillance for Cancer Doesn’t Increase Malpractice Risk
MDedge Hematology and Oncology
A Banned Chemical That Is Still Causing Cancer
MDedge Hematology and Oncology